THOUSAND OAKS, California-Increases in hemoglobin levels appear to improve the physical, functional, emotional, and psychological well-being of cancer patients with anemia. Based on the combined results of two randomized, controlled clinical trials, data supporting this statement were presented by Joel D. Kallich, PhD, associate director, health economics and epidemiology, at Amgen, Thousand Oaks, California.
THOUSAND OAKS, CaliforniaIncreases in hemoglobin levels appear to improve the physical, functional, emotional, and psychological well-being of cancer patients with anemia. Based on the combined results of two randomized, controlled clinical trials, data supporting this statement were presented by Joel D. Kallich, PhD, associate director, health economics and epidemiology, at Amgen, Thousand Oaks, California.
Participants in the trials, conducted in the United States, Canada, Europe, and Australia, received concomitant chemotherapy and darbepoetin alfa (Aranesp) or placebo over a 12-week period. Patients were then asked to complete a questionnaire including items from three survey instruments.
Physical Scores Improve
All domains measured by the FACT-An scales rose as hemoglobin increased, particularly the physical and functional scores, Dr. Kallich reported. "The FACT-Fatigue scale is the domain that is hypothesized to be the most sensitive to hemoglobin change," Dr. Kallich said. "As hemoglobin increases, by 2 or more grams per deciliter, we observe an improvement in the FACT-Fatigue Scale score of approximately 4 points. This is in contrast to those patients whose hemoglobin decreases, and whose fatigue scale score shows a decrease of about 1.5 points." (see Figure 1).
The results of the analysis are sensitive to methods of estimating missing data (such as information on people who dropped out or died during the trial) as well as variability in the patient population. When one sets a threshold for measuring patient improvement, for example, a 10% or more improvement in FACT-Fatigue Scale scores, 13% more patients receiving darbepoetin alfa had a 10% or more improvement in their scale scores than those patients receiving placebo, Dr. Kallich reported. "Patients in the placebo group received transfusions at the discretion of physicians, therefore the effect that is shown here is the benefit above those receiving transfusions. So what you are seeing here is an independent effect," he said.
Measured by the BSI scale, depressive symptoms and anxiety decreased from baseline to the end of trial. "As hemoglobin increases, approximately 45% of patients reported a 10% or more improvement in their feelings of depression, anxiety, and overall health. This is an increase of approximately 15% from those patients whose hemoglobin did not improve," Dr. Kallich said.
"We’re in the process right now of taking this data and comparing it to national norms and also psychiatric patient norms. And what we’ve found is that the cancer patient norms are a lot closer to the national norms, of course, than a psychiatric inpatient." He added that improvement in psychological outcomes observed during the trials is moving cancer patients even closer to the national norms.
The results from these studies are confirmatory of physician-reported benefits of increasing hemoglobin in oncology and other patient populations.